Sandy Spring Bank Cellectar Biosciences, Inc. Transaction History

Sandy Spring Bank

  • $2.4 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 01, 2020
SELL
$11.0 - $31.7 $66 - $190
-6 Closed
0 $0
Q4 2019

Feb 06, 2020
BUY
$10.6 - $24.1 $63 - $144
6 New
6 $0

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $12.4M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email